NEW HORIZONS FORUM

Program
February 3, 2017
Palace Hotel • San Francisco, CA

Speeding the development of new therapies and diagnostics for glaucoma patients

Presented by

GLAUCOMA RESEARCH FOUNDATION

Follow the meeting on Twitter: #Glaucoma360
Glaucoma Research Foundation thanks the following sponsors for their generous support:

Platinum Sponsors

- aerie Pharmaceuticals, Inc.
- ALLERGAN
- BAUSCH + LOMB
- NOVARTIS
- Shire

Gold Sponsors

- Abbott
- Medical Optics

Silver Sponsors

- Alcon
- SURGICAL
- New World Medical
- Ora
- Santen
- Sun Ophthalmics
- Zeiss

Bronze Sponsors

- Akorn, Inc.
- Beaver-Visitec International
- Diopsys
- Ellex
- Glaukos Corporation
- Heidelberg Engineering
- Icare USA, Inc.
- Inotek Pharmaceuticals
- IRIDEX
- Lumenis
- Nidek, Inc.
- Ocular Therapeutix
- Ophthalmic Mutual Insurance Company
- Optovue, Inc.

Wi-Fi sponsored by NOVARTIS — Password: GRF360
Welcome

It is our sincere pleasure to welcome you to the 6th Annual Glaucoma 360: New Horizons Forum. This catalyst meeting, hosted by Glaucoma Research Foundation, highlights the many unmet medical needs that remain in the field of glaucoma and brings together the essential elements needed to advance the development of new ideas into clinical practice to prevent and manage the disease more effectively. With the overwhelming success of our previous meetings, this annual forum continues to grow and provides the ultimate opportunity for collaboration and networking needed to advance new concepts to reality for glaucoma patients.

Our meeting objectives today are to:

- Bring together nationally and internationally respected leaders in medicine, science, business, venture capital, and the FDA to present and discuss new and emerging ideas in the field of glaucoma therapy.
- Facilitate collaboration between these essential groups in order to accelerate the development and approval of the next generation of therapies and diagnostic devices.
- Broaden our understanding of glaucoma from various sectors engaged in research and development to advance new and effective options to help patients preserve their sight.

Today would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board and Program Committee who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at the Palace Hotel.

Over the past six years, there have been many advances in the glaucoma space including the development of novel treatments, introduction of new companies, important acquisitions and mergers, as well as several IPO’s. As a result, the field has grown substantially and provides doctors and patients with more options to treat and manage the disease than ever before.

All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Thank you for your ongoing partnership in our mission. Together, we can truly make a difference in the lives of people living with glaucoma.

Adrienne L. Graves, PhD
Co-Founder, Co-Chair
New Horizons Forum
Director,
Glaucoma Research Foundation

Andrew G. Iwach, MD
Co-Founder, Co-Chair
New Horizons Forum
Board Chair,
Glaucoma Research Foundation
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 8:00 am</td>
<td>Breakfast and Exhibits</td>
<td></td>
</tr>
<tr>
<td>8:00 – 8:06 am</td>
<td>Welcome and Opening Remarks</td>
<td>Adrienne L. Graves, PhD and Andrew G. Ivach, MD, Co-Founders and Co-Chairs, Glaucoma 360</td>
</tr>
<tr>
<td>8:06 – 8:32 am</td>
<td>Opening Keynote Address: Drs. Henry and Frederick Sutro Memorial Lecture</td>
<td>“Optical Coherence Tomography—Past, Present, and Future”</td>
</tr>
<tr>
<td></td>
<td>Speaker: Joel S. Schuman, MD, FACS, Professor &amp; Chairman of Ophthalmology, NYU Langone Medical Center, New York University School of Medicine; Professor &amp; Chair of Electrical &amp; Computer Engineering, NYU Tandon School of Engineering</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morning Catalyst: Steven D. Vold, MD, President, Vold Vision; Chief Medical Editor, Glaucoma Today</td>
<td></td>
</tr>
<tr>
<td>8:32 – 9:28 am</td>
<td>New Horizons in Telemedicine</td>
<td>Lama Al-Aswad, MD, MPH, Associate Professor of Ophthalmology, Columbia University Medical Center, Louis R. Pasquale, MD, Professor of Ophthalmology, Harvard Medical School; Director of Glaucoma Service, Director of Teleretinal Program, Massachusetts Eye and Ear, Mark B. Horton, OD, MD, Director, Indian Health Services/ Joslin Vision Network Teleophthalmology Program</td>
</tr>
<tr>
<td></td>
<td>Morning Catalyst: Steven D. Vold, MD, President, Vold Vision; Chief Medical Editor, Glaucoma Today</td>
<td></td>
</tr>
<tr>
<td>9:28 – 9:35 am</td>
<td>Industry Spotlight: Aerie Pharmaceuticals</td>
<td>Casey Kopczynski, PhD, Chief Scientific Officer, Aerie Pharmaceuticals</td>
</tr>
<tr>
<td>9:35 – 10:12 am</td>
<td>FDA: Getting to New Horizons</td>
<td>Eugene de Juan, Jr., MD, Founder and Vice Chairman, ForSight Labs, Gary Novack, PhD, President, PharmaLogic Development, Inc.; Visiting Professor of Pharmacology and Ophthalmology, University of California, Davis, School of Medicine, Tieuvi Nguyen, PhD, Chief, Intraocular and Corneal Implants Branch, Division of Ophthalmic and Ear, Nose and Throat Devices, U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>10:12 – 10:37 am</td>
<td>Break, Exhibits and Networking Opportunity</td>
<td></td>
</tr>
<tr>
<td>10:37 – 11:30 am</td>
<td>New Horizons in Pharmaceuticals</td>
<td>Alan Crandall, MD, Presidential Professor of Ophthalmology and Visual Services, Senior Vice Chair, Director of Glaucoma and Cataract; Co-Director, Division of International Ophthalmology, John A. Moran Eye Center Global Outreach Division, University of Utah, David A. Holland, MD, MBA, Chief Medical Officer and SV, Ora, Inc.</td>
</tr>
<tr>
<td></td>
<td>Presenting Companies: Aerie Pharmaceuticals—Thomas Mitro, President and COO, Bausch + Lomb—Jason Vittitow, PhD, Sr. Director, Clinical Affairs, Inotek Pharmaceuticals—Cadmus Rich, MD, MBA, CPE, VP of Medical Affairs and Clinical Development, Allergan, Inc.—Aziz Mottiwalla, VP of Marketing, US Eye Care, Shire—Robert J. Dempsey, MBA, Vice President and US Franchise Head, Ophthalmics</td>
<td></td>
</tr>
<tr>
<td>11:30 – 11:38 am</td>
<td>Industry Spotlight: Novartis Alcon Pharmaceuticals</td>
<td>Melissa Liew, Medical Unit Head, Ophthalmology, Novartis Alcon Pharmaceuticals</td>
</tr>
<tr>
<td>11:38 – 12:15 pm</td>
<td>Funding Innovation: Venture Capital Panel Discussion</td>
<td>Emmett Cunningham, Jr., MD, PhD, MPH, Managing Partner, Clarus Ventures, William J. Link, PhD, Co-Founder and Managing Director, Versant Ventures</td>
</tr>
<tr>
<td></td>
<td>Panelists: Mark S. Blumenkranz, MD, MMS, H.J. Smead Professor of Ophthalmology, Byers Eye Institute at Stanford, Firas M. Rahhal, MD, Partner, ExSight Capital Management; Partner, Retina Vitreous Associates Medical Group; Associate Clinical Professor of Ophthalmology, UCLA School of Medicine, Jeffry Weinhouff, Managing Partner, Visionary Ventures</td>
<td></td>
</tr>
<tr>
<td>12:15 – 1:15 pm</td>
<td>Networking Buffet Luncheon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Afternoon Catalyst: Robert D. Fechtner, MD, Empire Innovation Scholar and Chair, Department of Ophthalmology, Upstate Medical University; Executive Vice President, World Glaucoma Association</td>
<td></td>
</tr>
<tr>
<td>1:15 – 2:02 pm</td>
<td>Industry Panel Discussion: Glaucoma Devices and Pharmaceuticals</td>
<td>James D. Brandt, MD, Director of Glaucoma Service, Professor of Ophthalmology &amp; Vision Science, UC, Davis</td>
</tr>
</tbody>
</table>
# Program and Speakers

**Moderators:**
- K. Angela Macfarlane, JD, President and CEO, ForSight Labs

**Panelists:**
- Aerie Pharmaceuticals, Inc.—Thomas Mitro, President and COO
- Abbott Medical Optics, Inc.—Jane Rady, DVP Business Development
- Alcon Surgical—Shawn O’Neil, Head, Sales and Marketing Surgical Glaucoma, U.S. Surgical Division
- Allergan, Inc.—Aziz Mottiwal, VP of Marketing, US Eye Care
- Bausch + Lomb—Tracy M. Valorie, BS, MBA, SVP, GM, B+L Pharmaceuticals, Valeant Women’s Health
- Carl Zeiss Meditec, Inc.—Angelo Rago, Head of Ophthalmic Diagnostics
- New World Medical—Rafael Chan, Chief Commercial Officer
- Novartis Alcon Pharmaceuticals—Melissa Liew, Medical Unit Head, Ophthalmology
- Santen Pharmaceuticals Co., Ltd.—Naveed Shams, MD, PhD, Head of Global R&D and Chief Scientific Office, Senior Corporate Office
- Shire—Susan Benton, Head of Business Development, Ophthalmics
- Sun Ophthalmics—Mark C. Jasek, PhD, Vice President, Medical & Scientific Affairs

## 2:02 – 2:09 pm
**Industry Spotlight: Bausch + Lomb**  
**Speaker:** Tracy M. Valorie, BS, MBA, SVP, GM, B+L Pharmaceuticals, Valeant Women’s Health

## 2:09 – 3:10 pm
**New Horizons in Glaucoma Drug Delivery**  
**Moderators:**  
L. Jay Katz, MD, Professor of Ophthalmology, Jefferson Medical College; Director of Glaucoma Service, Wills Eye Institute  
Cheryl Rowe-Rendleman, PhD, CEO and Managing Consultant, Omar Consulting Group

**Presenting Companies:**
- Envisia Therapeutics—Benjamin Yerxa, PhD, President
- Eximere—Ishay Attar, Co-Founder and CEO
- Graybug Vision, Inc.—Jeffrey L. Cleland, PhD, President and CEO
- Massachusetts Eye and Ear/Harvard Medical School—Joseph B. Ciolino, MD, Asst. Professor of Ophthalmology
- Mati Therapeutics, Inc.—Christopher A. Muller, Chief Commercial Office
- Ocular Therapeutix—Jonathan H. Talamo, MD, Chief Medical Office

## 3:10 – 3:35 pm
**Break, Exhibits and Networking Opportunity**

## 3:35 – 3:45 pm
**“Animal Models of Glaucoma and their Translatability into the Clinic”**  
**Speaker:** Andy Whitlock, PhD, Vice-President, Pre-Clinical Research & Development, Ora, Inc.

## 3:45 – 4:07 pm
**“Biomarkers and Drug Discovery: Integrating therapeutic and diagnostic trials”**  
**Introduction:** David J. Calkins, PhD, Denis M. O’Day Professor of Ophthalmology and Visual Sciences, Vice-Chairman and Director for Research, The Vanderbilt Eye Institute; Director, Vanderbilt Vision Research Center, Vanderbilt University Medical Center

**Speaker:** Jeffrey L. Goldberg, MD, PhD, Professor and Chair of Ophthalmology, Byers Eye Institute, Stanford University

## 4:07 – 4:14 pm
**Industry Spotlight: Shire**  
**Speaker:** Robert J. Dempsey, MBA, Vice President and US Franchise Head, Ophthalmics, Shire

## 4:14 – 5:13 pm
**New Horizons in Glaucoma Devices**  
**Moderators:**  
Malik Y. Kahook, MD, Slater Family Endowed Chair of Ophthalmology, Vice Chair, Clinical & Translational Research; Chief, Glaucosa Service & Director, Glaucosa Fellowship, Professor of Ophthalmology, University of Colorado Anschutz Medical Campus  
Thomas W. Samuelson, MD, Founding Partner, Minnesota Eye Consultants; Adjunct Professor of Ophthalmology, University of Minnesota

**Presenting Companies:**
- Alcon Surgical—Steven D. Vold, MD, President, Vold Vision; Chief Medical Editor, Glaucosa Today
- Allergan, Inc.—Michael R. Robinson, MD, VP, Therapeutic Area Head, Anterior Segment and Consumer Eye Care
- Equinox LLC—John Berdahl, MD, Founder and CEO
- Glaucos—Jeff Wells, PharmD, Senior VP of Clinical, Regulatory and Quality
- InnFocus, Inc. (A Santen Company)—Russ Trenary, President & CE
- Ivantis, Inc.—Brett Trauthen, Chief Scientific Office
- New World Medical—Nathan M. Radcliffe, MD, Assistant Professor of Ophthalmology, Director of Glaucosa Service, NYU Langone Medical Center, New York Eye Surgery Center

## 5:13 – 5:23 pm
**Forum Summation:** Ruth D. Williams, MD, President, Wheaton Eye Clinic

## 5:23 – 5:25 pm
**Closing Remarks:** Adrienne L. Graves, PhD and Andrew G. Iwach, MD

## 5:30 – 7:00 pm
**Reception, Exhibits, and Networking**
Advisory Board

Stuart B. Abelson, MBA
President and Chief Executive Officer, Ora, Inc.

Anthony P. Adamis, MD
Vice President and Global Head of Ophthalmology Genetech, Inc.

Ernest Cavin, PhD
President, Haag-Streit USA

Paul Chaney
President and Chief Executive Officer, PanOptica, Inc.

George A. Cioffi, MD
Chairman, Department of Ophthalmology Columbia University College of Physicians and Surgeons

Alan S. Crandall, MD
Presidential Professor of Ophthalmology and Visual Services Senior Vice Chair, Director of Glaucoma and Cataract Co-Director, Division of International Ophthalmology, John A. Moran Eye Center

Emmett Cunningham, Jr., MD, PhD, MPH
Managing Partner, Clarus Ventures

Eugene de Juan, Jr., MD
Founder and Vice-Chairman, ForSight Labs

David Guyer, MD
Partner SV Life Sciences Advisers, LLC

Eve Higginbotham, SM, MD
Vice Dean, Perelman School of Medicine, University of Pennsylvania

H. Dunbar Hoskins, Jr., MD
Co-Founder and Director, Glaucoma Research Foundation Former Executive Vice President, American Academy of Ophthalmology

Wende Hutton
General Partner, Canaan Partners

Ralf Kuschnereit, PhD
Head of Digital Innovation and Business Analytics, Carl Zeiss Meditec, Inc.

Eliot Lazar, MD
President, eCON Medical

Paul Lee, MD, JD
F. Bruce Fralick Professor and Chair, Department of Ophthalmology and Visual Sciences Director, W.K. Kellogg Eye Center, University of Michigan

Richard L. Lindstrom, MD
Founder, Minnesota Eye Consultants, PA

William J. Link, PhD
Co-Founder and Managing Director, Versant Ventures

Cynthia Mattox, MD, FACS
Director of the Glaucoma and Cataract Service, New England Eye Center Associate Professor and Vice-Chair, Department of Ophthalmology Tufts University School of Medicine
### Advisory Board

<table>
<thead>
<tr>
<th>Name</th>
<th>Position / Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Mazzo</td>
<td>Operating Partner, Versant Ventures, Chairman and Chief Executive Officer, AcuFocus</td>
</tr>
<tr>
<td>J. Casey McGlynn, JD</td>
<td>Partner, Wilson Sonsini Goodrich &amp; Rosati</td>
</tr>
<tr>
<td>George Spaeth, MD</td>
<td>Louis Esposito Research Professor of Ophthalmology, Director Emeritus, Glaucoma Service, Wills Eye Hospital/Jefferson Medical College</td>
</tr>
<tr>
<td>Ellen Strahlman, MD, MHS</td>
<td>Chief Medical Officer and Senior Vice President, Research and Development, Becton, Dickinson &amp; Company</td>
</tr>
<tr>
<td>Gary D. Novack, PhD</td>
<td>President, PharmaLogic Development, Inc.</td>
</tr>
<tr>
<td>Tracy M. Valorie, BS, MBA</td>
<td>Senior Vice President, General Manager of Ophthalmology Rx, Bausch + Lomb Pharmaceuticals</td>
</tr>
<tr>
<td>David E.I. Pyott, CBE</td>
<td>Former Chairman of the Board, President and Chief Executive Officer, (1998–2015), Allergan, Inc.</td>
</tr>
<tr>
<td>Robert N. Weinreb, MD</td>
<td>Chairman and Director, Shiley Eye Center, Director, Hamilton Glaucoma Center, University of California, San Diego</td>
</tr>
<tr>
<td>Thomas W. Samuelson, MD</td>
<td>Founding Partner, Minnesota Eye Consultants, Adjunct Associate Professor of Ophthalmology, University of Minnesota</td>
</tr>
<tr>
<td>Ruth D. Williams, MD</td>
<td>President, Wheaton Eye Clinic</td>
</tr>
<tr>
<td>Kuldev Singh, MD, MPH</td>
<td>Professor of Ophthalmology, Director, Glaucoma Service, Stanford University School of Medicine</td>
</tr>
<tr>
<td>M. Roy Wilson, MD, MS</td>
<td>President, Wayne State University</td>
</tr>
</tbody>
</table>

### New Horizons Forum

**Sincere Thanks to Our Media and Strategic Partners**

- Bryn Mawr Communications
- Elsewhere Advertising
- Healthegy
- Market Scope
- Ophthalmology Innovation Summit
- Ophthalmology Times
- Rotary Club of San Francisco
- touchOphthalmology
PUSHING THE FUTURE OF GLAUCOMA TO LIGHT

With BOLD new treatments on the horizon and a dedication to enhancing the field of glaucoma, Allergan is committed to an even better tomorrow for you and your patients.
Program Committee

Ike Ahmed, MD, FRCSC
Assistant Professor, Faculty of Medicine, University of Toronto
Clinical Assistant Professor, University of Utah

Eydie G. Miller-Ellis, MD
Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania

Lama A. Al-Aswad, MD
Associate Professor of Ophthalmology, Columbia University Medical Center

Mildred M.G. Olivier, MD
Associate Clinical Professor, Rosalind Franklin University of Medicine and Science
Associate Clinical Professor, Midwestern University
Chief Executive Officer and Founder, Midwest Glaucoma Center, P.C.

Anne L. Coleman, MD, PhD
Frances and Ray Stark Professor of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at UCLA
Professor of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles

Joel S. Schuman, MD, FACS
Chairman of Ophthalmology
New York University

Robert D. Fechtner, MD
Empire Innovation Scholar and Chair, Department of Ophthalmology, Upstate Medical University
Executive Vice President, World Glaucoma Association

Robert Stamper, MD
Professor of Clinical Ophthalmology
Director, Glaucoma Service
University of California, San Francisco

Larry Haimovitch
Founder, Haimovitch Medical Technology Consultants

James C. Tsai, MD, MBA, FACS
Chair of Ophthalmology, Mount Sinai Health System
President, New York Eye & Ear Infirmary

L. Jay Katz, MD
Director, Glaucoma Service, Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University

Devesh K. Varma, Beng, MD, FRSC
Assistant Professor, Faculty of Medicine
University of Toronto

Richard A. Lewis, MD
Sacramento Eye Consultants
Former Director of Glaucoma, University of California, Davis

Steven Vold, MD
Founder and Chief Executive Officer, Vold Vision
Chief Medical Editor, Glaucoma Today

Shan Lin, MD
Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director, Glaucoma Fellowship Program, Department of Ophthalmology, University of California, San Francisco

Barbara Wirostko, MD
Clinical Adjunct Associate Professor
University of Utah School of Medicine
Adrienne L. Graves, PhD
Independent Director: Akorn, TearLab Corporation, Aerpio Therapeutics, Envisia Therapeutics, Encore Vision, Inc., and Nicox S.A.
Co-Founder and Co-Chair, Glaucoma 360
Board of Directors
Glaucoma Research Foundation

Adrienne L. Graves, PhD is a visual scientist by training and a global industry leader in ophthalmology. From 2002 to 2010 Dr. Graves was President and CEO of Santen Inc., the US arm of Japan’s largest ophthalmic pharmaceutical company. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories in various Research & Development roles including Director of International Ophthalmology.

She is a Director on several Foundation Boards including American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AA) Foundation (Emeritus), KeepYourSight, Retina Global, and Himalayan Cataract Project. She also serves on the Corporation Committee for the Brown University Medical School. Dr. Graves is a co-founder of Ophthalmic Women Leaders (OWL) and Glaucoma 360. She received the 2015 Catalyst Award from Glaucoma Research Foundation for her dedication and leadership in advancing ophthalmic innovation.

Dr. Graves did her undergraduate studies at Brown University, her PhD work at the University of Michigan, and a postdoctoral fellowship in visual neuroscience at the University of Paris.

Andrew G. Iwach, MD
Executive Director, Glaucoma Center of San Francisco and Executive Director, Glaucoma Research and Education Group, Co-Founder and Co-Chair, Glaucoma 360, Chair, Board of Directors, Glaucoma Research Foundation

Dr. Iwach has been a member on the Board of Directors for the Glaucoma Research Foundation since 2000 and is currently serving as its Chair. He is Co-Founder of the Eye Surgery Center of San Francisco.

He currently serves as a scientific reviewer for many top professional publications, and in 2004 he received the Academy’s Senior Achievement Award and in 2012 the Academy’s Secretariat Award.

Dr. Iwach is an Associate Clinical Professor of Ophthalmology in the Department of Ophthalmology at the University of California San Francisco.

He is on the clinical faculty at California Pacific Medical Center.

He teaches courses and lectures extensively on glaucoma. Dr. Iwach is actively involved in clinical research, as well and his focus has included mitomycin-C use in filtering surgery, application of optical coherence tomography in glaucoma, selective laser trabeculoplasty, numerous drug trials and more.

He has published more than 40 peer-reviewed papers and book chapters.

Abbott

Developing advanced, life-improving vision technologies for people of all ages.

abbottmmedioloptics.com
Leadership

Thomas M. Brunner
President and Chief Executive Officer, Glaucoma Research Foundation
Steering Committee, Glaucoma 360

Mr. Brunner joined Glaucoma Research Foundation in 2003 after a successful 30-year career in the ophthalmic laser business. He helped introduce major advances in eye care including laser photocoagulation to prevent vision loss from diabetic retinopathy, laser treatment of secondary cataracts, and laser treatment for glaucoma.

Since joining Glaucoma Research Foundation, Tom has helped to more than double revenue and focus on innovative research to understand how glaucoma steals sight and find a cure. He received a “Lifetime Achievement” award from the American Society for Laser Medicine and Surgery for his contributions and 25 years of service on their Board of Directors.

Tom actively supports development of new products to help those with glaucoma and other eye diseases as an advisor or board member for startup companies in the eye care field.

He graduated from Lehigh University with a degree in electrical engineering and received an MBA from the University of Delaware.

L. Jay Katz, MD
Director, Glaucoma Service, Wills Eye Hospital
Professor of Ophthalmology, Jefferson Medical College

Dr. Katz has wide-ranging interests in glaucoma, including drug evaluation, laser and medical management in glaucoma treatment, optic nerve scanning methodologies, and glaucoma surgical techniques.

He is on the advisory boards of pharmaceutical and glaucoma device companies, including Glaukos, Bausch + Lomb, Allergan, Aerie, and Merck.

Dr. Katz received his BA from Case Western Reserve University and his MD from Yale University School of Medicine. He completed his ophthalmology residency at Yale and then moved to Wills Eye Hospital for his glaucoma subspecialty training.

Ruth D. Williams, MD
President, Wheaton Eye Clinic
Board of Directors, Glaucoma Research Foundation

Dr. Williams is the President of the Wheaton Eye Clinic, a 74-year-old ophthalmology practice that provides subspecialty eye care to more than 140,000 patients annually.

She is a past president of the American Academy of Ophthalmology, representing ophthalmology at the AMA for nearly a decade and chairing its specialty section.

After attending Rush Medical College, Dr. Williams completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

Opening Keynote Address
Drs. Henry and Frederick Sutro Memorial Lecture

Joel S. Schuman, MD, FACS
Professor & Chairman of Ophthalmology
NYU Langone Medical Center
New York University School of Medicine
Professor of Electrical & Computer Engineering
NYU Tandon School of Engineering

Joel S. Schuman, MD, is Professor and Chairman of Ophthalmology and Professor of Neuroscience and Physiology at NYU Langone Medical Center, NYU School of Medicine, and Professor of Electrical & Computer Engineering at NYU Tandon School of Engineering. Dr. Schuman and his colleagues were first to identify a molecular marker for human glaucoma, published in Nature Medicine in 2001.

Continuously funded by the National Eye Institute as a principal investigator since 1995, he is an inventor of optical coherence tomography (OCT), used world-wide for ocular diagnostics. Dr. Schuman has published more than 350 peer-reviewed scientific journal articles.
DEDICATED
to changing the **Glaucoma** landscape

We believe everyone should have the best possible vision throughout their lives.

As the leader in eye care, Alcon is dedicated to changing the glaucoma landscape through a focus on **science, innovation and leadership**, and by developing a glaucoma portfolio designed to address unmet patient needs at all stages of the disease.

We are committed to long-term investments in research and development in order to advance the treatment of patients living with glaucoma and reduce the burden of disease around the world.
Speakers, Moderators and Participants

Lama Al-Aswad, MD, MPH
Associate Professor of Ophthalmology
Columbia University Medical Center

Dr. Al-Aswad is an Associate Professor of Ophthalmology at CUMC and the glaucoma fellowship director. She received her MD from Damascus University, and completed a research fellowship at the MEEI, Harvard Medical School. She completed her residency at SUNY Downstate and Fellowship at UT Memphis. She received her MPH from Columbia University, Mailman School of Public Health with an emphasis on healthcare policy and management. She has been the director of the glaucoma screening program since 2006 and in 2016 she launched Tele-ophtalmology for the four leading causes of blindness. She has received many awards and served on multitude of committees including the Columbia University Implementation of the Academic Tracks committee.

Ishay Attar, Msc, MBA
Co-Founder and CEO
Eximore Ltd.

Mr. Attar is a serial entrepreneur and medtech innovator. He is an expert in biomaterials and drug delivery systems with 18 years of experience in solving some most challenging unmet medical needs through use of innovative technologies. He has successfully launched several start-ups, as founder, CEO, chairman, VP business development and product manager. Mr. Attar is the founder of Eximore, LifeBond, OutSense, BioChange, and others.

Susan Benton
Head of Ophthalmics Business Development
Shire

Ms. Benton heads Shire’s commercial strategy and business development efforts for the ophthalmics franchise. She has over 18 years of ophthalmic industry experience. Before Shire she worked in BD&L at B+L Pharmaceuticals prior to the acquisition by Valeant. She was a Co-Founder and Head of Marketing and Sales of a start-up venture, Sirion Therapeutics. During that time, she was instrumental in the development and launch of Durezol® and Zirgan®, now owned by Alcon/Novartis and B+L/Valeant respectively. She has also served as a strategic consultant for over a dozen ophthalmic companies. Before joining the ophthalmic community, Ms. Benton ran the sales organization for J&J Lifescan. She earned an Executive MBA from the University of South Florida and a BS in Biology from Muhlenberg College.

John Berdahl, MD
Chief Executive Officer and Founder
Equinox LLC

Dr. Berdahl specializes in Refractive, Cataract, Corneal and Glaucoma Surgery. He graduated from Mayo Medical School and completed an internship at the Mayo Clinic Scottsdale, residency at Duke University and a fellowship at Minnesota Eye Consultants. He has won numerous national awards including Harvard University’s Claes Dohlman Award, the Resident Writers Award, and was recently named in the Top 40 under 40 ophthalmologists worldwide. He serves on the Vision for Mars program and started a device company to treat diseases caused by an imbalance between intraocular and intracranial pressure. Dr. Berdahl has published numerous peer-reviewed articles. His research interests include cerebrospinal fluid pressure in glaucoma, MIGS, ReLACS, and intraocular lens design. He holds a leadership role in EyeCare America and has completed surgical mission trips worldwide.

Mark S. Blumenkranz, MD, MMS
H.J. Smead Professor of Ophthalmology
Department of Ophthalmology
Stanford University
Byers Eye Institute at Stanford

Dr. Blumenkranz is H.J. Smead Professor in the Department of Ophthalmology at Stanford University. He received his undergraduate, graduate degree, and medical education at Brown University as well as the Graduate School of Business at Stanford. He completed his internship in surgery and ophthalmic residency training at Stanford and a fellowship at the Bascom Palmer Eye Institute. He served as Chairman of the Department of Ophthalmology at Stanford and the Founding Director of the Byers Eye Institute at Stanford until 2015.

Dr. Blumenkranz has a longstanding interest and expertise in university corporate technology transfer and early stage biomedical company development having either founded or served on the Boards of Directors of a number of successful medical drug and device companies.

James D. Brandt, MD
Professor of Ophthalmology and Vision Science
Director of Glaucoma Service
University of California, Davis

Dr. Brandt received his BS from Yale University and an MD from Harvard Medical School, then pursued a two-year post-doctoral research fellowship at the Schepens Eye Research Institute before his residency at the Doheny Eye Institute.

Dr. Brandt’s clinical practice is limited to glaucoma, with a particular focus on infantile and pediatric. His research interests are in the material properties of the eye as they affect the measurement of intraocular pressure and the physiology of outflow resistance. He is currently collaborating with researchers in the fields of nanotechnology, micro-fabrication and biomedical engineering to develop new methods to measure outflow resistance in the living human eye. He has served as the Principal Investigator of numerous clinical trials.
Dr. David J. Calkins is the Vice-Chairman and Director for Research for the Vanderbilt Eye Institute and the Denis M. O’Day Professor of Ophthalmology & Visual Sciences for the Vanderbilt University School of Medicine, where he has been faculty since 2004. He is also Director of the Vanderbilt Vision Research Center, home to some 50 vision scientists across disciplines and departments at Vanderbilt University. Professor Calkins is a leading authority on the neurobiological basis of vision loss in blinding eye disease. He has received over 40 federal, foundation and industry grants for his widely-cited work on neuronal protection and repair for conditions that affect the retina and optic nerve.

Rafael Chan
Chief Commercial Officer
New World Medical

Mr. Chan recently joined New World Medical as Chief Commercial Officer. Prior to joining New World Medical, Mr. Chan spent over 16 years with Alcon in a variety of commercial strategy and leadership positions across Surgical and Pharmaceutical franchises, most recently as Head of Marketing for US Surgical. Mr. Chan holds a Bachelor’s Degree and MBA, both from Vanderbilt University.

Joseph B. Ciolino, MD
Assistant Professor of Ophthalmology
Massachusetts Eye and Ear/Harvard Medical School

Dr. Ciolino is a clinician scientist at Massachusetts Eye and Ear and conducts research that has been supported by the National Institutes of Health, the DOD, and other funding organizations. He also has served as an advisor and medical monitor for over 25 ophthalmic clinical trials. Dr. Ciolino’s primary research focus is the development of a drug-eluting contact lens. The contact lens has demonstrated sustained release of therapeutic drug levels for up to one month and efficacy in glaucomatous monkeys. This technology has been covered by popular news services including CNN, The Economist, Reuters News Service and Scientific American.

Jeffrey L. Cleland, PhD
President and CEO
GrayBug Vision, Inc.

Dr. Cleland has 25 years of industry experience in research and development. He has played major roles in obtaining more than $450 million in capital including over $300 million in capital raised as CEO of Versartis (VSAR), where he led one of top biotech IPOs of all time. He has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, he held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as early work on Lucentis®, Avastin®, Omnitarg® and Kadcyla®. He holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and 4 books, and holds several issued patents.

Alan S. Crandall, MD
Presidential Professor of Ophthalmology and Visual Services, Senior Vice Chair, Director of Glaucoma and Cataract
Co-Director, Division of International Ophthalmology, John A. Moran Eye Center Global Outreach Division, University of Utah

Dr. Crandall is a member of the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, American Glaucoma Society, the European Society of Cataract and Refractive Surgeons, as well as the International Intra-Ocular Implant Club. He graduated from the University of Utah, receiving his medical degree from the University of Utah School of Medicine. Dr. Crandall completed his internship in surgery at the University of Pennsylvania Medical Center as well as his residency and fellowship in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He joined the University of Utah Ophthalmology Department in 1981.

Emmett Cunningham, Jr., MD, PhD, MPH
Managing Partner
Clarus Ventures

Dr. Cunningham joined Clarus Ventures in 2006 with more than 20 years experience in the biomedical and biopharmaceutical sectors. He also founded and serves as Chairman of the Ophthalmology Innovation Summit (OIS). He is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications. He is Director of the Uveitis Service at California Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford University, and a Research Associate at The Francis I. Proctor Foundation, UCSF School of Medicine. Dr. Cunningham received his MD and MPH from Johns Hopkins University, his PhD from the University of California, San Diego, and completed his residency and fellowship at UCSF. He completed additional fellowships at Moorfields Eye Hospital in London and the Wilmer Eye Institute.

Karim Damji, MD
Professor and Chair
Department of Ophthalmology and Visual Sciences
University of Alberta

Dr. Damji is Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Alberta and former residency program director. He completed his residency in Ophthalmology at the University of Ottawa and fellowship training in glaucoma at Duke University. He has a passion for promoting Institutional capacity development, training of glaucoma sub specialists, and models of teleglaucoma to enhance access and quality of glaucoma care for underserviced populations within Canada and Sub Saharan Africa.
Karim has authored over 120 peer review publications, contributed to Canadian evidence based guidelines on glaucoma, and co-authored recent editions of Shields’ Textbook of Glaucoma. He has received awards for excellence in teaching, research and humanism.

**Eugene de Juan, Jr., MD**
Founder and Vice-Chairman, ForSight Labs

Dr. de Juan serves as Vice-Chairman of ForSight Labs and is the Jean Kelly Stock Distinguished Professor in Ophthalmology at UCSF. He has participated in the development of a number of new technologies with over 100 products including the “retina chip,” minimally invasive retinal surgery, ocular drug delivery and the founding of nine venture-funded companies.

He has previously served as Professor of Ophthalmology at the University of Southern California and CEO at the Doheny Retina Institute, Co-Director of Vitreoretinal Service at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, Director of the Microsurgery Advanced Design Laboratory, and Joseph E. Green Professor of Ophthalmology.

He completed his medical degree and internship training at the University of South Alabama College of Medicine.

**Robert Dempsey**
Vice President and US Franchise Head, Ophthalmics
Shire

Since joining Shire in 2014 to help form the Ophthalmics franchise, Robert Dempsey’s accomplishments include U.S. launch of Xiidra® (lifitegrast ophthalmic solution) 5% for the treatment of both signs and symptoms of dry eye disease; and building a diverse pipeline of investigational candidates, built through strategic acquisition of four companies to date, and organic growth. Robert has more than 20 years of experience at companies including Bausch + Lomb, Inspire, Muro Pharmaceuticals, Inc. and Allergan, Inc. He holds a Master’s in Business Administration and a Bachelor of Science from Northeastern University.

**Jeffrey L. Goldberg, MD, PhD**
Professor and Chair of Ophthalmology
Byers Eye Institute
Stanford University

Dr. Goldberg is Professor and Chair of Ophthalmology at Byers Eye Institute at Stanford University. His clinical effort is focused on patients in need of medical or surgical intervention for glaucoma and other retinal and optic nerve diseases. His research is in neuroprotection and regeneration of retinal ganglion cells and the optic nerve, and his laboratory is developing stem cell and nanotherapeutics approaches for eye repair.

Dr. Goldberg received his B.S. magna cum laude from Yale University, and his MD and PhD from Stanford University where he made significant discoveries about the failure of optic nerve regeneration. He did his clinical training in ophthalmology and then in glaucoma at the Bascom Palmer Eye Institute, and was awarded a fellowship from the Heed Foundation. He directs an NIH-funded research laboratory, his goal is to translate scientific discoveries to patient therapies.

**Ying Han, MD, PhD**
Associate Professor of Ophthalmology
Glaucoma Service
University of California, San Francisco

Dr. Han is an Associate Professor of Ophthalmology and ophthalmologist at the University of California at San Francisco. She completed her fellowship at UCSF. In addition to her clinical work in glaucoma clinical and surgical management, she is an active clinical researcher with over 10 years of experience. Her areas of interest are glaucoma laser, development of visual field, new glaucoma device design, and glaucoma surgical clinic trials. She is currently a principal investigator on two clinical trials at UCSF. Her research has focused on improving glaucoma diagnosis, surgical outcome of current glaucoma surgery and designing new devices for future glaucoma surgery.

**David A. Hollander, MD, MBA**
Chief Medical Officer and SVP
Ora, Inc.

Dr. Hollander is Chief Medical Officer and SVP at Ora where he oversees pharmaceutical and device clinical and preclinical programs for Ora’s innovative global clients addressing the wide range of unmet needs in ophthalmology. Prior to joining Ora, Dr. Hollander served as VP of Clinical Development as well as VP and Head of Eye Care for Global Medical Affairs at Allergan.

Dr. Hollander holds a BS in Chemistry from Stanford, an MBA from Wharton, and an MD from the University of Pennsylvania. He completed an ophthalmology residency at UCSF and a Heed Fellowship in Cornea & External-Ocular Disease at the Jules Stein Eye Institute, UCLA, where he is Assistant Clinical Professor of Ophthalmology.
Dr. Mark Horton is an optometrist and ophthalmologist, and has worked at the Phoenix Indian Medical Center since 1986 as Chief of the Eye and ENT Departments. Dr. Horton was appointed to develop and direct a national teleophthalmology program for the Indian Health Service in 1999. This program uses telemedicine to remotely diagnose and manage diabetic retinopathy at more than 100 sites in 25 states. In addition to his medical, surgical, and telemedicine practice Dr. Horton is active in DICOM and IHE-Eye Care committees for the development of interoperability standards in eye care health information technology (HIT).

Dr. Kahook is Professor of Ophthalmology and The Slater Family Endowed Chair in Ophthalmology at the University of Colorado School of Medicine. He is Vice Chair of Clinical and Translational Research and is chief of the glaucoma service and director of the glaucoma fellowship at the University of Colorado Eye Center. Dr. Kahook authored over 300 peer-reviewed manuscripts, abstracts, and book chapters. He was named New Inventor of the Year for the University of Colorado in 2009 and Inventor of the Year in 2010.

Dr. Kahook has also received numerous awards and filed for over 30 patents with 20 licensed by companies for development. Four of his devices are currently in human trials or available globally for clinical use. He serves on several editorial boards and is a consultant to the FDA’s Ophthalmic Device Division.

Dr. Katz has wide-ranging interests in glaucoma, including drug evaluation, laser and medical management in glaucoma treatment, optic nerve scanning methodologies, and glaucoma surgical techniques. He is on the advisory boards of pharmaceutical and glaucoma device companies, including Glaukos, Mati Therapeutics, Allergan, Aerie Pharmaceuticals, Inotek, Aerpio Therapeutics, Alcon, InnFocus, Alimera Sciences, Ocular Therapeutix and ForSight VisionS.

Dr. Katz received his BA from Case Western Reserve University and his MD from Yale University School of Medicine. He completed his ophthalmology residency at Yale and then moved to Wills Eye Hospital for his glaucoma subspecialty training.

Dr. Link specializes in early-stage investing in medical devices at Versant. With extensive knowledge of medical devices, particularly in ophthalmology, his operating experiences spans more than 25 years in general management in the healthcare industry.

Perhaps Dr. Link’s greatest operational success was as Chief Executive Officer in Chiron Vision, a subsidiary of Chiron Corporation specializing in ophthalmic surgical products, which was sold to Bausch + Lomb in 1997.

He founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986.

Dr. Link earned his Bachelor’s, Master’s, and Doctorate degrees from Purdue University.
UNITING OVER 500 LEADERS

IN THE DEVELOPMENT OF GROUND-BREAKING OPHTHALMIC TECHNOLOGIES

MAY 4, 2017
SHERATON GRAND LOS ANGELES
711 SOUTH HOPE STREET • LOS ANGELES, CA, 90017

OIS.NET
Speakers, Moderators and Participants

K. Angela MacFarlane, JD  
President and Chief Executive Officer  
ForSight Labs

ForSight Labs is a company focused on creating a community where innovation and practical application of ideas are combined to create companies focused on improving the lives of visually impaired patients. Since 2005, ForSight has started six companies focused on key needs in ophthalmology such as treatment of glaucoma and macular degeneration. Prior to joining ForSight Labs, Ms. Macfarlane served as Chief Technology Counsel to The Foundry and as Technology Counsel for Thomas J. Fogarty, MD, where she participated in all aspects of early stage technology review, licensing, intellectual property management and company creation. Ms. MacFarlane received her BA in Business Administration from San Francisco State University, and her JD from Golden Gate University School of Law.

Christopher A. Muller  
Chief Commercial Officer  
Mati Therapeutics, Inc.

Chris Muller is currently the Chief Commercial Officer of Mati Therapeutics, and previously held the same position at QLT Inc. Prior to joining QLT, Mr. Muller was responsible for several business units at Abbott Medical Optics including Vice President of Eye Care, Medical Marketing and the Refractive Business Unit. Major global brand responsibility included VISX® and iFS laser platforms, contact lens solutions, artificial tear development and commercialization, plus multiple ophthalmic surgical products. In addition, Mr. Muller was employed at Allergan Inc. for 15 years, where he built an extensive background across all ocular pharmaceutical, surgical products and Botox®, including sales, health economics, worldwide medical marketing, and product management.

Thomas Mitro  
President and Chief Operating Officer  
Aerie Pharmaceuticals, Inc.

Mr. Mitro has over 30 years of pharmaceutical industry experience in sales and marketing, commercial operations, and business development. Prior to joining Aerie, he most recently served as Vice President, Sales and Marketing at Omeros Corporation, a publicly traded clinical-stage biopharmaceutical company. Before this, he was Vice President, Sales and Marketing at ISTA Pharmaceuticals, where he was instrumental in building commercial operations and launching several eye care products. At the time of ISTA’s acquisition by Bausch + Lomb, ISTA had grown to become the third largest branded prescription eye care business in the U.S. Previously, he held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. He received his BS degree from Miami University.

Tieuvi Nguyen, PhD  
Chief, Intraocular and Corneal Implants Branch  
Division of Ophthalmic and Ear, Nose, and Throat Devices  
U.S. Food and Drug Administration

Dr. Nguyen joined FDA in 2011 and currently serves as the Branch Chief of the Intraocular and Corneal Implants Branch of FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices (DOED). Her responsibilities involve oversight of various scientific and regulatory policies related to the premarket approval of these ophthalmic devices. Prior to joining the FDA, Dr. Nguyen held numerous positions in the pharmaceutical and finance industries.

Aziz Mottiwal  
Vice President of Marketing, US Eye Care  
Allergan Inc.

Aziz Mottiwal, Allergan’s Vice President of US Eyecare Marketing, is a 15+ year healthcare veteran, with nearly a decade of experience specifically in Eyecare. In his current role he leads the marketing efforts, strategy, and promotion of Allergan’s eyecare products in Dry Eye, Glaucoma, and OTC Tears. His experience spans a broad range of commercial responsibilities, in numerous therapeutic areas. His expertise has contributed to strategies for both in-line and development products, as well as licensing and acquisition projects. He holds a BS in Biochemistry from UC San Diego, and an MBA from the Marshall School of Business at the University of Southern California.

Gary D. Novack, PhD  
President  
PharmaLogic Development, Inc.  
Visiting Professor of Pharmacology and Ophthalmology, University of California Davis, School of Medicine

Dr. Novack is the founder and president of PharmaLogic Development, Inc.—a consultancy providing development expertise to pharmaceutical and medical device companies specializing in ophthalmology and other local therapies. He has played a key role in the approval of over 40 ophthalmic products. He is a member of many professional societies, including the Glaucoma Research Society, and has served in leadership roles in the American society of clinical Pharmacology and Therapeutics.

Dr. Novack received his BA from the University of California Santa Cruz, his PhD in Pharmacology and Toxicology from the University of California Davis, and his postdoctoral fellowship in neurophysiology at the University of California Los Angeles.
Our motivation.

To learn how Santen is advancing the ophthalmic field, visit www.santen.com.

Santen is proud to sponsor the Glaucoma Research Foundation and the 2017 New Horizons Forum.

Speakers, Moderators and Participants

Shawn O’Neil
Head, Sales and Marketing Surgical Glaucoma
U.S. Surgical Division
Alcon Surgical

Mr. O’Neil graduated from Princeton University with a degree in Economics and has spent his entire 21-year career at Alcon in various Sales and Marketing leadership roles within the Ophthalmic/Optometric industry. Specific to glaucoma, he has led teams that sold glaucoma medications, launched the Ex-PRESS Glaucoma Filtration Device, and now focuses on the launch of the CyPass Micro-stent System.

Louis R. Pasquale, MD
Professor of Ophthalmology
Harvard Medical School
Director of Teleretinal Program
Massachusetts Eye & Ear

Dr. Pasquale is Professor of Ophthalmology at Harvard Medical School. He directs the Massachusetts Eye and Ear Teleretinal Program and co-directs Harvard’s Glaucoma Center of Excellence. Dr. Pasquale is a member of the PLOS One and American Journal of Ophthalmology editorial boards. He currently serves as chair of the American Glaucoma Society Research Committee. Dr. Pasquale is an NIH Principal Investigator with continuous support since 2006 and currently serves as an NEI Advisory Council member. His research leverages the rich resources available in large population based cohorts to discover primary prevention strategies in the open-angle glaucomas.

Nathan Radcliffe, MD
Assistant Professor of Ophthalmology,
Director of Glaucoma Service
NYU Langone Medical Center
New York Eye Surgery Center

Dr. Radcliffe is a board certified ophthalmologist who is an experienced glaucoma and cataract surgeon. Previously, Dr. Radcliffe served as the Director of the Glaucoma Service at Weill Cornell Medical College for six years, and he now is the director of the glaucoma service at NYU Langone Medical Center. Dr. Radcliffe is on the AAO Skills Transfers Advisory Committee, is the Chair of the Multimedia Committee for the American Glaucoma Society, and serves on the Glaucoma Clinical Committee for the Association of Cataract and Refractive Surgery. He was chief ophthalmology resident at New York University and was chief glaucoma fellow at the New York Eye and Ear Infirmary.

Santen A Clear Vision For Life

Her eye disease. Our motivation.

Image is designed to represent nondescript visual impairment and is not intended to be medically accurate. For illustrative purposes only.

Santen is proud to sponsor the Glaucoma Research Foundation and the 2017 New Horizons Forum.

To learn how Santen is advancing the ophthalmic field, visit www.santen.com.

At Santen, our single focus in ophthalmology enables research of novel therapies in glaucoma, uveitis, and dry eye/corneal disorders—therapies determined to challenge eye disease, one patient at a time.

© 2017 Santen Pharmaceutical Co., Ltd. All rights reserved. 01/2017
Speakers, Moderators and Participants

Jane Rady
Divisional Vice President
Business Development
Abbot Medical Optics, Inc.

Prior to joining Abbott Medical Optics, Ms. Rady was a director and the Chief Executive Officer of Integrated Genomics, Inc., held senior positions within G.D. Searle & Co., and headed venture investing in Monsanto focusing on emerging technologies and businesses in biotechnology.

She serves as a board member on the University of California Irvine’s Biomedical Engineering Corporate Advisory Board, as a member of the board of directors for the Medical Device Manufacturer’s Association, is a board member of Ophthalmic Women Leaders, and chair of the Southern California chapter of Ophthalmic Women Leaders.

Ms. Rady began her career with Abbott Laboratories. She received her Bachelor and Master of Science from the University of Illinois in molecular biology/microbiology and her MBA from Northwestern’s Kellogg School of Management.

Angelo Rago
Head of Ophthalmic Diagnostics
Carl Zeiss Meditec

Mr. Rago is Head of Ophthalmic Diagnostics (ODx), consisting of the Retina & Glaucoma and the Routine Diagnostics businesses. He joined ZEISS as Head of Business Sectors and Innovation within the Strategic Business Unit Ophthalmic Systems in Dublin.

Previously, Mr. Rago held various management positions in Equipment Operations & Global Customer Care for Abbott Medical Optics (AMO). Prior to AMO, he spent 17 years with Siemens Medical Solutions, where he held a number of senior positions in both Service and Product Development areas. He holds a Bachelor's Degree in Mechanical Engineering and an Executive Certification in Innovation & Strategy from MIT’s Sloan School of Business.

Dr. Cheryl Rowe-Rendleman
CEO and Managing Consultant
Omar Consulting Group, LLC

Cheryl Rowe-Rendleman, PhD is a clinical research and development professional who, since 2005 has served as CEO of Omar Consulting Group, an ophthalmology consulting practice that specializes in creating business, regulatory, and clinical development know-how for people and companies with interests in eye diseases.

A graduate of Princeton University with graduate fellowships in developmental and degenerative ophthalmic diseases from the University of Texas and University of California San Francisco Medical Schools, Cheryl has participated in over 100 US and Ex-US clinical development programs in the areas of macular degeneration, diabetic retinopathy, ocular inflammation, anti-infectives, refractive disorders, glaucoma, and ocular surface disease.

Michael R. Robinson, MD
Vice-President, Therapeutic Area Head
Anterior Segment and Consumer Eye Care
Allergan, Inc.

Michael R. Robinson, MD, is a board-certified ophthalmologist who completed 3 years of post-doctoral/fellowship training at the National Eye Institute with a focus on ocular drug delivery. Dr. Robinson joined Allergan in 2005 and currently serves as Vice President and Therapeutic Area Head of Anterior Segment and Consumer Eye Care. Given his broad clinical and research background, Dr. Robinson has served in multiple leadership roles at Allergan including Global Project Team Lead and Clinical Lead on projects related to ocular drug delivery in dry eye, retina and glaucoma therapeutic areas. He has over 20 issued patents that include Bimatoprost SR and Brimonidine DDS, both in late stages of clinical development.

Dr. Thomas W. Samuelson, MD
Attending Surgeon
Minnesota Eye Consultants, P.A.

Dr. Samuelson specializes in glaucoma and anterior segment surgery. He received his subspecialty training in glaucoma at the Wills Eye Hospital in Philadelphia. He is a founding partner of Minnesota Eye Consultants in Minneapolis, Adjunct Associate Professor of Ophthalmology at the University of Minnesota, past President of the International Society of Spaeth Fellows/ Wills Eye Hospital Glaucoma Fellows Society, and serves on the Governing Board of Directors of the American Glaucoma Society.

Dr. Samuelson is a past chairman of the ASCRS Glaucoma Clinical Advisory Committee and an Associate Secretariat for the AAO annual meeting.

Michael R. Robinson, MD
Vice-President, Therapeutic Area Head
Anterior Segment and Consumer Eye Care
Allergan, Inc.

Michael R. Robinson, MD, is a board-certified ophthalmologist who completed 3 years of post-doctoral/fellowship training at the National Eye Institute with a focus on ocular drug delivery. Dr. Robinson joined Allergan in 2005 and currently serves as Vice President and Therapeutic Area Head of Anterior Segment and Consumer Eye Care. Given his broad clinical and research background, Dr. Robinson has served in multiple leadership roles at Allergan including Global Project Team Lead and Clinical Lead on projects related to ocular drug delivery in dry eye, retina and glaucoma therapeutic areas. He has over 20 issued patents that include Bimatoprost SR and Brimonidine DDS, both in late stages of clinical development.

Dr. Thomas W. Samuelson, MD
Attending Surgeon
Minnesota Eye Consultants, P.A.

Dr. Samuelson specializes in glaucoma and anterior segment surgery. He received his subspecialty training in glaucoma at the Wills Eye Hospital in Philadelphia. He is a founding partner of Minnesota Eye Consultants in Minneapolis, Adjunct Associate Professor of Ophthalmology at the University of Minnesota, past President of the International Society of Spaeth Fellows/ Wills Eye Hospital Glaucoma Fellows Society, and serves on the Governing Board of Directors of the American Glaucoma Society.

Dr. Samuelson is a past chairman of the ASCRS Glaucoma Clinical Advisory Committee and an Associate Secretariat for the AAO annual meeting.

Dr. Thomas W. Samuelson, MD
Attending Surgeon
Minnesota Eye Consultants, P.A.

Dr. Samuelson specializes in glaucoma and anterior segment surgery. He received his subspecialty training in glaucoma at the Wills Eye Hospital in Philadelphia. He is a founding partner of Minnesota Eye Consultants in Minneapolis, Adjunct Associate Professor of Ophthalmology at the University of Minnesota, past President of the International Society of Spaeth Fellows/ Wills Eye Hospital Glaucoma Fellows Society, and serves on the Governing Board of Directors of the American Glaucoma Society.

Dr. Samuelson is a past chairman of the ASCRS Glaucoma Clinical Advisory Committee and an Associate Secretariat for the AAO annual meeting.

Dr. Thomas W. Samuelson, MD
Attending Surgeon
Minnesota Eye Consultants, P.A.

Dr. Samuelson specializes in glaucoma and anterior segment surgery. He received his subspecialty training in glaucoma at the Wills Eye Hospital in Philadelphia. He is a founding partner of Minnesota Eye Consultants in Minneapolis, Adjunct Associate Professor of Ophthalmology at the University of Minnesota, past President of the International Society of Spaeth Fellows/ Wills Eye Hospital Glaucoma Fellows Society, and serves on the Governing Board of Directors of the American Glaucoma Society.

Dr. Samuelson is a past chairman of the ASCRS Glaucoma Clinical Advisory Committee and an Associate Secretariat for the AAO annual meeting.
CONCISE, PEER-REVIEWED, OPEN ACCESS OPINION based ARTICLES & VIDEOS from KEY OPINION LEADERS
ACCESS and DOWNLOAD FREE

Connect with us and join the debate

www.touchOPHTHALMOLOGY.com
Speakers, Moderators and Participants

Naveed Shams, MD PhD
Head of Global R&D and Chief Scientific Officer
Senior Corporate Officer,
Santen Pharmaceutical Co., Ltd

Since joining Santen as Vice President of Clinical Affairs, Dr. Shams has served as Head of Global Clinical Development and Medical Affairs, and, most recently, as President and CEO of Santen US. With over 20 years of experience in global drug development, Dr. Shams has played a critical role in bringing several products to market, including Lucentis®, Zaditor®/Zaditen®, and Rescula®. His industry experience spans companies such as Genentech, Novartis, OPKO Health, Storz Ophthalmics, and On Demand Therapeutics.

Dr. Shams received his MD from Dow Medical College in Karachi, Pakistan, and his PhD from the University of South Carolina in microbiology and immunology. He completed fellowships in cornea and external diseases at Harvard Medical School, and histocompatibility and immunogenetics at Massachusetts General Hospital.

Sameer Trikha, MBA, FRCOphth
Founder and Chief Medical Officer
Visulytix

Mr Sameer Trikha is a practicing Consultant Ophthalmic surgeon specialising in glaucoma at King’s College Hospital in London, and is also Chief Medical Officer for Visulytix. Having completed his Ophthalmology residency in the UK he subsequently undertook a clinical research fellowship at the prestigious Singapore Eye Research Institute, followed by a clinical fellowship at Moorfields Eye Hospital. He has published widely in the field of glaucoma, and authored two books. He recently completed an MBA in healthcare management and innovation at Imperial College London, and is passionate about leveraging data to develop high quality, scalable solutions in healthcare.

Jonathan H. Talamo, MD
Chief Medical Officer
Ocular Therapeutix

Jonathan Talamo, MD, joined Ocular Therapeutix in 2016, bringing more than 25 years of experience as an ophthalmologist, innovator, and clinical investigator. During his career, Dr. Talamo has advised numerous early-to late-stage ophthalmology companies and served as an investigator for clinical trials leading to FDA approvals of PRK, LASIK and refractive cataract surgery technologies. He was also Associate Professor of Ophthalmology at Harvard Medical School and served as Director of the Massachusetts Eye and Ear Infirmary (MEEI) Waltham, a Harvard-affiliated teaching hospital.

Dr. Talamo received his MD degree from The Johns Hopkins University School of Medicine and completed an ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins.

Russ Trenary
President and Chief Executive Officer
InnFocus, Inc.
A Santen Company

Russ Trenary is President & CEO for InnFocus, Inc., a Santen company, pioneering microsurgical solutions for glaucoma. He has led, or been a named officer, in medical device companies for over 20 years, and has raised over $800M of capital.

His managerial experience includes specific interfacing in marketing, sales, finance, R&D, regulatory, and manufacturing. He has turned unprofitable $100M divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at AMO (NYSE:EYE). He also has vast experience with large volume product launches and acquisitions like Pharmacia Surgical, Ioptex, VIXS, Intralase, and Optical Micro Systems.

Tracy M. Valorie, BS, MBA
Senior Vice President
General Manager
B + L Pharmaceuticals
Valeant Women’s Health

Ms. Valorie is the Senior Vice President and General Manager of Bausch + Lomb Pharmaceuticals and Valeant Women’s Health and previously served as the Global Head of Glaucoma. Prior to joining B + L, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products, mid-stage development portfolio, and long range planning.

Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing, and strategic planning.

Ms. Valorie has held board membership seats at The Glaucoma Foundation, ARVO foundation for Eye Research, and OWL.

Jason L. Vittitow, PhD
Senior Director
Clinical Affairs
Bausch + Lomb

Jason Vittitow, PhD has over 20 years of academic and industry experience in ocular pharmacology research. He is currently Senior Director of Clinical Affairs at Bausch + Lomb and the R&D program lead for latanoprostene bunod. Prior to B + L Dr. Vittitow held various positions at Inspire Pharmaceuticals including managing preclinical and clinical activities around the advancement of Rho kinase and latrunculin platforms for glaucoma. Prior to joining Inspire, Dr. Vittitow was a Glaucoma Research Fellow at the Duke University Eye Center and the University of North Carolina at Chapel Hill. He received his PhD in Ophthalmology and Visual Sciences from the University of Louisville School of Medicine.
Speakers, Moderators and Participants

**Steven D. Vold, MD**
Founder and Chief Executive Officer
Vold Vision
Chief Medical Editor
Glaucoma Today

Dr. Vold founded Vold Vision after previously serving as Vice Chairman of the Department of Ophthalmology and Director, Division of Glaucoma at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas.

He has been listed in the Consumer’s Research Council of America’s Guide to America’s Top Ophthalmologists every year since 2002. He currently serves as Chief Medical Editor of Glaucoma Today, and co-founded the American-European Congress of Ophthalmic Surgery.

Dr. Vold also co-founded the Silicon Valley-based ophthalmic device company Ocunetics, Inc. whose intellectual property was exclusively licensed by Iridex Corporation in 2011.

**Jeffry Weinhuff**
Managing Partner
Visionary Ventures

Jeffry Weinhuff has been active in private equity investment for 30 years. Jeff is Managing Partner of Visionary Venture Fund, an Ophthalmology fund uniquely structured to leverage its relationship with over two-dozen premier ophthalmology KOL partners. The fund invests in later stage venture in both anterior segment and vitreous and retina.

**Jeff Wells, PharmD**
Senior VP of Clinical, Regulatory, and Quality
Glaukos

Jeff Wells has served as Glaukos’ Senior VP for Clinical, Regulatory, and Quality Affairs since 2008. Prior to this, Jeff was Sr. VP of Product Development at Bioform, and held various roles at Santen Pharmaceutical including VP US R&D, VP Clinical and Regulatory Affairs for the US and Europe, and Director of Marketing. Prior to Santen, he worked at Bausch & Lomb, where he launched Lotemax and several other products. Jeff holds a BS and BA from Ohio Northern University, a Masters in Management (MBA) from the Kellogg School at Northwestern University, and a PharmD from the University of Florida.

**Andy Whitlock, PhD**
Vice President of Preclinical R&D
Ora, Inc.

Andy Whitlock, PhD, is VP of Preclinical R&D at Ora where he leads early stage drug development and lead candidate selection for Ora’s innovative clients addressing unmet needs in all ophthalmic indications. This includes in vivo pharmacology, PK, and safety models to management of IND-enabling studies. Dr. Whitlock was previously Director of Glaucoma Research at Lexicon Pharmaceuticals where his team screened over 3500 genes in search of novel glaucoma drug targets.

Dr. Whitlock holds a BS in biology from The Citadel and a PhD in Molecular Cell Biology from the Medical University of South Carolina.

**Ruth D. Williams, MD**
President,
Wheaton Eye Clinic

Dr. Williams is President of the Wheaton Eye Clinic, a 73-year-old ophthalmology practice that provides subspecialty eye care to more than 140,000 patients annually.

She is a past president of the American Academy of Ophthalmology, representing ophthalmology at the AMA for nearly a decade and chairing its specialty section.

After attending Rush Medical College, Dr. Williams completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

**Benjamin Yerxa, PhD**
Chief Executive Officer
Envisia Therapeutics

Dr. Yerxa is a co-founder of Envisia Therapeutics, an ophthalmic drug delivery company spun out of Liquidia Technologies. Previously, he was Vice President of Research and Development at Clearside Biomedical and the Executive Vice President and Chief of Research & Development at Inspire Pharmaceuticals, a top-ranked publicly-traded biotech company acquired by Merck & Co., Inc. During his time at Inspire, Dr. Yerxa helped the company build and commercialize a portfolio of innovative new products.

Throughout his 20-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs), and drug approvals.

His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular, and HIV.
The Optimum Partnership for IOP Control.

Both SLT and ABiC™ work to control IOP by a process of restoration of the natural outflow pathways.

SLT stimulates a process of cellular regeneration to create a healthier, more porous TM structure. Proven to be equivalent in safety and efficacy to prostaglandins, SLT achieves an average reduction in IOP of 30% when used as a first-line therapy.

ABiC™ is a new ab-interno MIGS procedure that flushes out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt. On average, ABiC™ achieves a mean IOP reduction of 30%.

Visit www.ellex.com/slt-abic-natural-partnership
Or, call us today on (855) 767-5784

LEARN MORE AT WWW.ELLEX.COM
“The MicroPulse P3’s titratability, repeatability and non-incisional nature provides a unique and versatile role in the treatment of glaucoma, one that can fit many areas of the glaucoma algorithm, address many challenging case scenarios, and be tailored to meet the needs of each patient.”

Nathan Radcliffe, MD
Founded in 1978 in San Francisco, Glaucoma Research Foundation was created to encourage innovative research to find better ways to care for people with glaucoma and ultimately find a cure.

Our Commitment to Education and Awareness

Glaucoma Research Foundation remains a principal source of information and support for doctors, patients and their families. We distribute more than 120,000 issues of our Gleams newsletter three times a year through the mail, by doctors’ offices and by email. Our website, www.glaucoma.org, helps over 4 million visitors annually with useful and accurate information. Both our website and our educational booklet “Understanding and Living with Glaucoma” continue to be primary resources for patients seeking to learn more about their glaucoma diagnosis, treatment options, and Glaucoma Research Foundation’s research initiatives.

Speeding the Development of New Therapies

In 2012, thanks to the leadership of Drs. Adrienne L. Graves and Andrew G. Iwach, we launched the Glaucoma 360 New Horizons Forum, an annual meeting dedicated to advancing the development of new glaucoma therapies and diagnostic devices. This unique gathering of medicine, industry, finance, and the FDA is a catalyst to advance novel ideas into clinical practice and assist patients in the near term. These innovative initiatives are made possible through generous philanthropic support from individuals, foundations and corporations. Glaucoma Research Foundation receives no government funding and thanks to good financial stewardship, 86% of all funds raised go directly to funding research and education. Please know that we are grateful for your participation in the 6th annual Glaucoma 360 and our efforts to eliminate this blinding disease. Thanks to you, the cure is truly in sight.

Fostering Collaborative Research

For more than three decades, Glaucoma Research Foundation has funded pioneering and transformational studies to advance the field of glaucoma. An important funding priority is fostering collaborative research in order to speed the pace of discovery. Landmark projects include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision, and the establishment of the Catalyst for a Cure (CFC) research consortium.

Established in 2001, our first CFC team focused on neuroprotection and fundamentally changed how the scientific and medical communities view vision loss in glaucoma. Based on this successful model, the second CFC team was recruited and charged with identifying new biomarkers to indicate the earliest signs of glaucoma. The researchers have moved their investigations from the laboratory into the clinic for human studies of the three most promising biomarkers they have identified. The impact of this research will be valuable for both patients and doctors as it has the potential to transform how glaucoma is diagnosed and managed in the future.

Please know that we are grateful for your participation in the 6th annual Glaucoma 360 and our efforts to eliminate this blinding disease. Thanks to you, the cure is truly in sight.

Thomas M. Brunner
President and Chief Executive Officer
We believe healthy eyes are the way of the future. Composed of world-renowned leaders in eye care, our vision is to inspire and to build a healthier way of living, starting with our patients’ eyes.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye.

See the future of eye care with Aerie.
www.aeriepharma.com